Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose exploration study of Favipiravir for the treatment of COVID-19 infection

Trial Profile

A dose exploration study of Favipiravir for the treatment of COVID-19 infection

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Acronyms TRIALS

Most Recent Events

  • 09 Mar 2020 New trial record
  • 02 Mar 2020 According to a Sihuan Pharmaceutical media release, the Trials study was officially initiated by the Ministry of Science and Technology in early February.
  • 02 Mar 2020 According to the Sihuan Pharmaceutical media release, the Trials study is led by Beijing Chaoyang Hospital affiliated with Capital Medical University, with Professor Tong Zhaohui as the leading researcher. Another two research centers include Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology and Wuhan Jinyintan Hospital.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top